Reduction in Hindquarter Vascular Resistance Supports 5-HT Receptor Mediated Hypotension

Overview

Journal Front Physiol

Date 2021 Jul 12

PMID 34248666

Citations 5

Authors

Bridget M Seitz

Stephanie W Watts

Gregory D Fink

Affiliations

Soon will be listed here.

Abstract

The 5-HT receptor is the primary mediator of both the (<hours) and (day-week) decreases in mean arterial pressure (MAP) during low dose 5-HT infusion in rats. Previous data show the hypotensive response during chronic 5-HT infusion is due to a decrease total peripheral resistance (TPR) and specifically splanchnic vascular resistance. We hypothesized that changes in vascular resistance in both the splanchnic and skeletal muscle vascular beds are critical to the cardiovascular effects mediated by the 5-HT receptor. Systemic and regional hemodynamic data were collected in conscious and anesthetized male rats using radiotelemetry, vascular catheters and transit-time flowmetry. Reversible antagonism of the 5-HT receptor was achieved with the selective antagonist SB269970 (33 μg/kg, iv). From the very beginning and throughout the duration (up to 5 days) of a low dose (25 μg/kg) infusion of 5-HT, TPR, and MAP were decreased while cardiac output (CO) was increased. In a separate group of rats, the contribution of the 5-HT receptor to the regional hemodynamic response was tested during 5-HT-induced hypertension. The decrease in MAP after 24 h of 5-HT (saline 83 ± 3 vs. 5-HT 72 ± 3 mmHg) was associated with a significant decrease in skeletal muscle vascular resistance (saline 6 ± 0.2 vs. 5-HT 4 ± 0.4 mmHg/min/mL) while splanchnic vascular resistance was similar in 5-HT and saline-treated rats. When SB269970 was administered acutely, MAP and skeletal muscle vascular resistance rapidly increased, whereas splanchnic resistance was unaffected. Our work suggests the most prominent regional hemodynamic response to 5-HT receptor activation paralleling the fall in MAP is a decrease in skeletal muscle vascular resistance.

Citing Articles

β-arrestin biased signaling is not involved in the hypotensive actions of 5-HT receptor stimulation: use of Serodolin.

Watts S, Garver H, Morisset-Lopez S, Suzenet F, Fink G Pharmacol Res. 2023; 199:107047.

PMID: 38157998 PMC: 11416702. DOI: 10.1016/j.phrs.2023.107047.

5-HT receptors mediate dilation of rat cremaster muscle arterioles in vivo.

Jackson W, Daci A, Thompson J, Fink G, Watts S Microcirculation. 2023; 30(5-6):e12808.

PMID: 37204759 PMC: 11409460. DOI: 10.1111/micc.12808.

Development of a 5-HT receptor antibody for the rat: the good, the bad, and the ugly.

Thompson J, Tragge W, Flood E, Schulz S, Lisabeth E, Watts S Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(10):2599-2611.

PMID: 37071157 PMC: 10497691. DOI: 10.1007/s00210-023-02482-w.

Activation of renal vascular smooth muscle TRPV4 channels by 5-hydroxytryptamine impairs kidney function in neonatal pigs.

Afolabi J, Michael O, Falayi O, Kanthakumar P, Mankuzhy P, Soni H Microvasc Res. 2023; 148:104516.

PMID: 36889668 PMC: 10258165. DOI: 10.1016/j.mvr.2023.104516.

Skin Vascular Resistance Decreases during 5-HT-Induced Hypotension in the Rat.

Butler B, Garver H, Watts S, Fink G Biomedicines. 2023; 11(2).

PMID: 36831083 PMC: 9953042. DOI: 10.3390/biomedicines11020547.

References

Villalon C, Centurion D . Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(1-2):45-63. DOI: 10.1007/s00210-007-0179-1. View

Eipel C, Abshagen K, Vollmar B . Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol. 2010; 16(48):6046-57. PMC: 3012579. DOI: 10.3748/wjg.v16.i48.6046. View

Diaz J, Ni W, Thompson J, King A, Fink G, Watts S . 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J Pharmacol Exp Ther. 2008; 325(3):1031-8. DOI: 10.1124/jpet.108.136226. View

Kaumann A, Levy F . 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006; 111(3):674-706. DOI: 10.1016/j.pharmthera.2005.12.004. View

Centurion D, Glusa E, Sanchez-Lopez A, Valdivia L, Saxena P, Villalon C . 5-HT7, but not 5-HT2B, receptors mediate hypotension in vagosympathectomized rats. Eur J Pharmacol. 2004; 502(3):239-42. DOI: 10.1016/j.ejphar.2004.08.050. View

Alsip N, Harris P . Receptor mediation of microvascular responses to serotonin in striated muscle. Am J Physiol. 1991; 261(5 Pt 2):H1525-33. DOI: 10.1152/ajpheart.1991.261.5.H1525. View

Berger M, Gray J, Roth B . The expanded biology of serotonin. Annu Rev Med. 2009; 60:355-66. PMC: 5864293. DOI: 10.1146/annurev.med.60.042307.110802. View

Saxena P, Villalon C . Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol. 1990; 15 Suppl 7:S17-34. View

Cowley Jr A . Long-term control of arterial blood pressure. Physiol Rev. 1992; 72(1):231-300. DOI: 10.1152/physrev.1992.72.1.231. View

10.

Dalton D, Feniuk W, Humphrey P . An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and DOCA-salt hypertensive rats. J Auton Pharmacol. 1986; 6(3):219-28. DOI: 10.1111/j.1474-8673.1986.tb00648.x. View

11.

El-Merahbi R, Loffler M, Mayer A, Sumara G . The roles of peripheral serotonin in metabolic homeostasis. FEBS Lett. 2015; 589(15):1728-34. DOI: 10.1016/j.febslet.2015.05.054. View

12.

Ayme-Dietrich E, Aubertin-Kirch G, Maroteaux L, Monassier L . Cardiovascular remodeling and the peripheral serotonergic system. Arch Cardiovasc Dis. 2016; 110(1):51-59. DOI: 10.1016/j.acvd.2016.08.002. View

13.

Lautt W . Regulatory processes interacting to maintain hepatic blood flow constancy: Vascular compliance, hepatic arterial buffer response, hepatorenal reflex, liver regeneration, escape from vasoconstriction. Hepatol Res. 2007; 37(11):891-903. PMC: 2981600. DOI: 10.1111/j.1872-034X.2007.00148.x. View

14.

Seitz B, Demireva E, Xie H, Fink G, Krieger-Burke T, Burke W . 5-HT does not lower blood pressure in the 5-HT knockout rat. Physiol Genomics. 2019; 51(7):302-310. PMC: 6689729. DOI: 10.1152/physiolgenomics.00031.2019. View

15.

Watts S, Darios E, Seitz B, Thompson J . 5-HT is a potent relaxant in rat superior mesenteric veins. Pharmacol Res Perspect. 2015; 3(1):e00103. PMC: 4317234. DOI: 10.1002/prp2.103. View

16.

Demireva E, Xie H, Flood E, Thompson J, Seitz B, Watts S . Creation of the 5-hydroxytryptamine receptor 7 knockout rat as a tool for cardiovascular research. Physiol Genomics. 2019; 51(7):290-301. PMC: 6689730. DOI: 10.1152/physiolgenomics.00030.2019. View

17.

Davis R, Pattison J, Thompson J, Tiniakov R, Scrogin K, Watts S . 5-hydroxytryptamine (5-HT) reduces total peripheral resistance during chronic infusion: direct arterial mesenteric relaxation is not involved. BMC Pharmacol. 2012; 12:4. PMC: 3418156. DOI: 10.1186/1471-2210-12-4. View

18.

Villalon C, Centurion D, Bravo G, de Vries P, Saxena P, Ortiz M . Further pharmacological analysis of the orphan 5-HT receptors mediating feline vasodepressor responses: close resemblance to the 5-HT7, receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000; 361(6):665-71. DOI: 10.1007/s002100000256. View

19.

de Vries P, De Visser P, Heiligers J, Villalon C, Saxena P . Changes in systemic and regional haemodynamics during 5-HT7 receptor-mediated depressor responses in rats. Naunyn Schmiedebergs Arch Pharmacol. 1999; 359(4):331-8. DOI: 10.1007/pl00005359. View

20.

Zinner M, Kasher F, Jaffe B . The hemodynamic effects of intravenous infusions of serotonin in conscious dogs. J Surg Res. 1983; 34(2):171-8. DOI: 10.1016/0022-4804(83)90057-4. View